Xglip M 1000mg/20mg Tablet is a combination oral antidiabetic medication containing Metformin hydrochloride 1000mg and Teneligliptin 20mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide class agent, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, prolongs the activity of incretin hormones, which increases insulin secretion and decreases glucagon release in a glucose-dependent manner. The synergistic action of these agents effectively lowers blood glucose levels, addressing both fasting and postprandial hyperglycemia. Xglip M is prescribed as an adjunct to diet and exercise to improve glycemic control in adult patients inadequately controlled on Metformin alone or in combination with other antidiabetic agents. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while hypoglycemia risk is generally low but may increase when combined with other antidiabetic drugs. Xglip M should be used under medical supervision to optimize therapeutic outcomes and minimize potential risks.